Morphine withdrawal enhances hepatitis C virus replicon expression

被引:32
作者
Wang, CQ
Li, Y
Douglas, SD
Wang, X
Metzger, DS
Zhang, T
Ho, WZ
机构
[1] Univ Penn, Childrens Hosp Philadelphia, Sch Med,Div Allergy & Immunol, Dept Pediat,Joseph Stokes Jr Res Inst, Philadelphia, PA 19104 USA
[2] Univ Penn, Sch Med, Dept Psychiat, Ctr Studies Addict, Philadelphia, PA 19104 USA
[3] Fudan Univ, Childrens Hosp, Div Clin Labs, Shanghai 200433, Peoples R China
关键词
D O I
10.1016/S0002-9440(10)61220-5
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
We previously demonstrated that morphine enhances hepatitis C virus (HCV) replication in human hepatic cells. Here we describe the impact of morphine withdrawal (MW), a recurrent event during the course of opioid abuse, on HCV replicon expression in human hepatic cells. MW enhanced both viral RNA and protein expression in HCV replicon cells. Blocking opioid receptors by treatment with naloxone after morphine cessation (precipitated withdrawal, PW) induced greater HCV repticon expression than MW. investigation of the mechanism responsible for MW or PW-mediated HCV enhancement showed that both MW and PW inhibited the expression of endogenous interferon-alpha (IFN-alpha) in the hepatic cells. This down-regulation of intracellular IFN-a expression was due to the negative impact of MW or PW on IFN-alpha promoter activation and on the expression of IFN regulatory factor 7 (IRF-7), a strong transactivator of the IFN-alpha promoter. in addition, both MW and PW inhibited the anti-HCV ability of recombinant IFN-alpha in the hepatic cells. These in vitro observations support the concept that opioid abuse favors HCV persistence in hepatic cells by suppressing IFN-alpha-mediated intracellular innate immunity and contributes to the development of chronic HCV infection.
引用
收藏
页码:1333 / 1340
页数:8
相关论文
共 53 条
[1]   Recovery, persistence, and sequelae in hepatitis C virus infection: A perspective on long-term outcome [J].
Alter, HJ ;
Seeff, LB .
SEMINARS IN LIVER DISEASE, 2000, 20 (01) :17-35
[2]   Epidemiology of hepatitis C [J].
Alter, MJ .
HEPATOLOGY, 1997, 26 (03) :S62-S65
[3]   Hepatitis C virus infection in the United States [J].
Alter, MJ .
JOURNAL OF HEPATOLOGY, 1999, 31 :88-91
[4]   Hepatitis C virus infection in injection drug users in Bavaria: Risk factors for seropositivity [J].
Markus Backmund ;
Kirsten Meyer ;
Martin Wächtler ;
Dieter Eichenlaub .
European Journal of Epidemiology, 2003, 18 (6) :563-568
[5]   Linking Toll-like receptors to IFN-α/β expression [J].
Barton, GHM ;
Medzhitov, R .
NATURE IMMUNOLOGY, 2003, 4 (05) :432-433
[6]   Rate of infection by blood-borne viruses in active heroin users in 3 Spanish cities [J].
Bassani, S ;
Toro, C ;
de la Fuente, L ;
Brugal, MT ;
Jiménez, V ;
Soriano, V .
MEDICINA CLINICA, 2004, 122 (15) :570-572
[7]   Combination therapy with interferon and ribavirin in the treatment of chronic hepatitis C infection [J].
Battaglia, AM ;
Hagmeyer, KO .
ANNALS OF PHARMACOTHERAPY, 2000, 34 (04) :487-494
[8]  
Biron CA, 1998, ADV EXP MED BIOL, V452, P143
[9]   Role of early cytokines, including alpha and beta interferons (IFN-α/β), in innate and adaptive immune responses to viral infections [J].
Biron, CA .
SEMINARS IN IMMUNOLOGY, 1998, 10 (05) :383-390
[10]   Efficient initiation of HCV RNA replication in cell culture [J].
Blight, KJ ;
Kolykhalov, AA ;
Rice, CM .
SCIENCE, 2000, 290 (5498) :1972-1974